Monash University: Drug repurposing is no panacea in race to treat COVID-19

repurposing drugs

Drug repurposing is no quick fix for developing new treatments for disease, including COVID-19, and  there are inherent dangers and pitfalls with translating drugs such as chloroquine, hydroxychloroquine, ivermectin and similar compounds to treat COVID-19, say a team of experts. The potential challenges and opportunities with drug repurposing are highlighted in a paper authored  by a cross-section […]

Read More… from Monash University: Drug repurposing is no panacea in race to treat COVID-19

COVID-19 Update: Chloroquine / Hydroxychloroquine and Azithromycin

Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook […]

Read More… from COVID-19 Update: Chloroquine / Hydroxychloroquine and Azithromycin